Kim W, Oh S, Kim H, Kim J, Gil J, Ku Y
J Clin Med. 2024; 13(14).
PMID: 39064094
PMC: 11278277.
DOI: 10.3390/jcm13144050.
Bonaz B, Sinniger V, Pellissier S
Front Neurosci. 2021; 15:650971.
PMID: 33828455
PMC: 8019822.
DOI: 10.3389/fnins.2021.650971.
Lambert J, De Schepper S, Speeckaert R
J Clin Med. 2021; 10(5).
PMID: 33802483
PMC: 7959457.
DOI: 10.3390/jcm10051040.
Slominski R, Tuckey R, Manna P, Jetten A, Postlethwaite A, Raman C
Genes Immun. 2020; 21(3):150-168.
PMID: 32203088
PMC: 7276297.
DOI: 10.1038/s41435-020-0096-6.
Iida T, Hida T, Matsuura M, Uhara H, Nakase H
Clin J Gastroenterol. 2019; 12(6):501-510.
PMID: 30838512
DOI: 10.1007/s12328-019-00958-y.
[What the rheumatologist can learn from the dermatologist-or: nobody can separate good friends : Interfaces of both domains].
Schakel K, Schirra A
Z Rheumatol. 2018; 77(6):484-492.
PMID: 29951861
DOI: 10.1007/s00393-018-0499-1.
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Hillson J, Mant T, Rosano M, Huntenburg C, Alai-Safar M, Darne S
Pharmacol Res Perspect. 2018; 6(1).
PMID: 29417761
PMC: 5817835.
DOI: 10.1002/prp2.380.
Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.
Andrade P, Lopes S, Gaspar R, Nunes A, Magina S, Macedo G
Dig Dis Sci. 2018; 63(3):746-754.
PMID: 29349693
DOI: 10.1007/s10620-018-4921-y.
Adverse reactions to biologic agents and their medical management.
Boyman O, Comte D, Spertini F
Nat Rev Rheumatol. 2014; 10(10):612-27.
PMID: 25112605
DOI: 10.1038/nrrheum.2014.123.
Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature.
Chiba M, Tsuda S, Tsuji T, Nakane K, Komatsu M, Miura Y
Medicine (Baltimore). 2014; 93(7):e54.
PMID: 25101989
PMC: 4602446.
DOI: 10.1097/MD.0000000000000054.
Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events.
Mendes D, Alves C, Marques F
Clin Rheumatol. 2013; 32(8):1207-14.
PMID: 23604594
DOI: 10.1007/s10067-013-2256-9.
Safety of biologic therapy in rheumatoid arthritis.
Woodrick R, Ruderman E
Nat Rev Rheumatol. 2011; 7(11):639-52.
PMID: 21989284
DOI: 10.1038/nrrheum.2011.145.
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
Stump K, Lu L, Dobrzanski P, Serdikoff C, Gingrich D, Dugan B
Arthritis Res Ther. 2011; 13(2):R68.
PMID: 21510883
PMC: 3132063.
DOI: 10.1186/ar3329.
Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.
Michelon M, Gottlieb A
Clin Cosmet Investig Dermatol. 2011; 3:79-84.
PMID: 21437062
PMC: 3047949.
DOI: 10.2147/ccid.s6186.
